HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

4- amino- 6- bromo- 1- (3,4- dihydroxy- 5- (hydroxymethyl)tetrahydrofuran- 2- yl)- 1H- pyrrolo(2,3- d)pyrimidine- 5- carboxamide

BMK-Y101 is the (2S,3S,4S,5S)-isomer; antineoplastic agent that inhibits both Cdk7 and Cdk9; structure in first source

Also Known As:

BMK Y101; BMK-Y101

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - Pyrimidine Nucleosides: 50
      - 4-amino-6-bromo-1-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1H-pyrrolo(2,3-d)pyrimidine-5-carboxamide: 1
Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleosides: 6847
  - Pyrimidine Nucleosides: 50
    - 4-amino-6-bromo-1-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1H-pyrrolo(2,3-d)pyrimidine-5-carboxamide: 1

Experts

1.	Cho, Seung-Ju: 1 article (06/2011)
2.	Kim, B Moon: 1 article (06/2011)
3.	Kim, Young-Jong: 1 article (06/2011)
4.	Lee, Seung-Ki: 1 article (06/2011)
5.	Surh, Young-Joon: 1 article (06/2011)

Related Diseases

1.	Neoplasms (Cancer) 06/03/2011 - "In this study, we showed that ibulocydine (an isobutyrate prodrug of the specific Cdk inhibitor, BMK-Y101) is a candidate anti-cancer drug for HCC. "

Related Drugs and Biologics

1.	Prodrugs
2.	(5- (4- amino- 6- bromo- 5- carbamoyl- 1H- pyrrolo(2,3- d)pyrimidin- 1- yl)- 3,4- dihydroxytetrahydrofuran- 2- yl)methyl isobutyrate